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ABSTRACT 
 
5-Fluorouracil (5-FU) is a pyrimidine analogue that is used as an anti-cancer drug but its therapeutic potential is 
limited by its hepatotoxicity. This study therefore, aimed at investigating the protective effect of crocin, a natural 
supplement, against 5-FU-induced liver injury. Male rats were administered with 5-FU (30 mg/kg b.wt i.p.) for 5 
days. Two groups of animals were either orally treated 3 days prior to or 3 days after 5-FU administration with 
crocin (40 mg/kg bwt). Another group was concurrently treated with crocin along with 5-FU administration. 
Biochemical variables indicative of liver injury, oxidative stress and liver histopathological alterations were 
thereafter determined. 5-FU administration markedly increased oxidative stress and markers of hepatic injury. Pre-, 
concurrent and post-treatment with crocin significantly reduced MDA, AOPP and LOOH levels and increased total 
antioxidant capacity compared to the 5-FU alone group, with improvement in the activities of the antioxidant 
enzymes, SOD, CAT and PONase. Liver injury was markedly reversed when AST, ALT and ALP activities 
estimated in the three treatment groups were compared to 5-FU group, but the restoration was incomplete, compared 
to the control. These biochemical variables were supported by histopathological examinations. The results indicate 
that crocin supplementation can ameliorate 5-FU-induced oxidative stress and liver injury in rat.  
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Introduction 
5-Fluorouracil (5-FU) is one of the most widely 
used antineoplastic drugs, mainly because of its 
efficacy against various malignancies [1, 2]. It is a 
fluoropyrimidine antimetabolite agent that plays a 
significant role in the treatment of cancers such as, 
colon and breast cancers, gastrointestinal cancers, head 
and neck cancers, and pancreatic cancer [2]. In the 
cancerous cell, it interferes with nucleoside metabolism 
and is incorporated into ribonucleic acid (RNA) and 
deoxyribonucleic acid (DNA), resulting in cytotoxicity 
and cell death [3, 4]. 5-FU is extensively metabolized 
in the liver and the production of toxic intermediate 
may trigger liver injury. Fluorouracil is reported to 
exhibit severe toxicity and adverse effects which have  
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restricted its chemotherapeutic use, limiting its 
potential as an effective anti-cancer agent [5]. 5-FU 
severe side effects are based on its systemic toxicity, 
including hepatotoxicity [6].  The pathophysiological 
mechanisms underlying this toxicity is yet to be 
elucidated but increased oxidative stress, apoptosis and 
inflammation have all  been associated with 5-FU 
toxicity [6].A number of natural agents have been 
reported to possess therapeutic properties. Notable 
among them is crocin, a hydrophilic carotenoid 
compound found in the perennial herb, Crocus sativus 
[7]. Several studies have shown that crocin displays 
important biological and pharmacological properties, 
exerting beneficial effects on many systems and organs 
[8,9]. These important properties include 
neuroprotection [10], anti-atherogenic [11], 
hypolipidemic [12], hypotensive [13], cardioprotective 
[15], antitumor [15] among others. Some of the 
proposed mechanisms by which crocin impacts its 
beneficial effects are linked to its antioxidant activity 
[8], cytotoxic effect [16], anti-inflammatory and 
immunomodulatory actions [17, 18]. Naghizadeh et al. 
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[20] reported that pretreatment with crocin lowers 
blood urea and creatinine in cisplatin-induced renal 
failure. Marked increase in total thiol and glutathione 
peroxidase concentrations, as well as, enhanced renal 
total antioxidant capacity have also been reported 
following oral administration of crocin [8]. 
Furthermore, crocin also protects against aflatoxin B1- 
and iron- induced hepatic damage [20, 21]. Although 
the exact hepatoproptective mechanisms of crocin have 
not been well elucidated, its protective actions have 
been proposed to be predicated on its antioxidant 
properties [7]. There is, however, a dearth of 
information about its ability to protect against 5-FU-
induced liver injury. But given that the efficacy of 
crocin as a therapeutic agent is based, among others, on 
its potential as an antioxidant and the advent of 
oxidative stress have been associated with hepatic 
toxicities, there is therefore a possibility that crocin, 
given its free radical scavenging and anti-oxidant 
properties, could prevent tissue oxidation generated by 
5-FU induced toxicity. The current study thus, aimed at 
evaluating the protective effect of crocin against 5-FU-
induced hepatic toxicity by the quantitative analyses of 
liver function enzymes in the plasma and investigating 
the oxidative imbalance of some oxidative stress 
indices, in addition to monitoring the level of 
intracellular antioxidant capacity. Furthermore, 
histopathological studies were carried out to assess 
ultrastructural changes in the liver. 
Materials and method 
Chemicals 
Crocin was purchased from Sigma –Aldrich, Germany. 
5-Fluorouracil was manufactured by Fidson Healthcare 
Pharmaceuticals, Nigeria. All other chemicals used 
were of analytical grade from Merck, India and Sigma-
Aldrich, Germany. 
Animals and treatment 
Male Wistar rats (150 – 180 g) were obtained from the 
animal house of the Faculty of Basic Medical Sciences, 
Ladoke Akintola University of Technology, 
Ogbomoso, Nigeria. The animals were kept in plastic 
cages under controlled conditions, fed with standard 
chow diet and water ad libitum, and acclimatized for 2 
weeks before the commencement of the experiment. 
Experimental design 
The rats were divided into 6 groups of 7 animals each. 
Control animals (Group I) received normal feed and 
water. 5-FU at therapeutic dose (20 mg/kg bwt) was 
administered intraperitoneally to Group II for 5 days. 
Group III were orally administered crocin (40 mg/kg 
bwt) in normal saline for 5 days. Animals in Group IV 
were pretreated with crocin for 3 days at the same dose 
as Group III before administered with 5-FU as in 
Group II. 5-FU and crocin were concurrently 
administered to rats in Group V, as in Groups II and III 
respectively while Group VI were treated as animals in 
Group II, at the end of which crocin was administered 
for 3 days as in Group III. At the end of the 
experimental period, the rats were sacrificed by 
cervical dislocation. Blood was collected by cardiac 
puncture into heparinzed tubes, centrifuged at 3, 000 g 
for 5 minutes and the plasma obtained was stored in 
Eppendoff tubes at -20oC. The liver was excised, 
washed with ice cold saline, blotted dry and then 
frozen until used for analysis. The dose for crocin was 
selected based on previous studies [22]. Experiment 
protocols were conducted according to the guidelines 
of the LAUTECH Department of Biochemistry 
guidelines for the care and use of laboratory animals. 
Biochemical analyses 
 Assay of alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) activity 
The activities of serum alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) were assayed by 
the method of Reitman and Frankel [23]. Alkaline 
phosphatase (ALP) was determined by the method of 
Bessey et al. [24]. 
Measurement of ferric reducing antioxidant power 
(FRAP) in plasma and tissues 
Total antioxidant capacity (TAC) in plasma and rat 
tissues was determined using the ferric reducing/ 
antioxidant power (FRAP) assay, developed by Benzie 
and Strain [25]. Briefly, 1.5 ml of working FRAP 
reagent (300 mM acetate buffer, pH 3.6, 10 mM 2,4,6-
tripyridyl-S-triazine in 40 mM HCl and  20 mM FeCl3 
in ratio 10:1:1) pre-warmed at 37 oC was vortex mixed 
with 50 mL sample (plasma and in the case of the 
tissues, 10% homogenate of either liver, kidney or 
brain). The test was performed at 37 °C and the 
absorbance was read at 593 nm. Aqueous solutions of 
known Fe2+ concentration were used for calibration.   
Determination of Advanced Oxidized Protein 
Products Concentration 
Spectrophotometric determination of advanced 
oxidized protein products (AOPP) levels in plasma and 
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tissues was performed by the method described by 
Witko et al. [26]. Each sample (0.4 mL of plasma, or 
10% tissue homogenate) in a tube, was treated with 1.6 
ml of Phosphate Buffered Saline (PBS) solution and 
0.1 ml 1.16 M potassium iodide (KI). This was 
followed 2 min later by 0.2 ml of acetic acid. The 
absorbance of the reaction mixture was immediately 
read at 340 nm against a blank containing 2 ml of PBS, 
0.1 mL of KI, and 0.2 ml of acetic acid. Concentration 
of AOPP was calculated by using the extinction 
coefficient of 26, 000 M-1 cm-1. 
Measurement of lipid hydroperoxides 
The concentrations of lipid hydroperoxides (LOOH) in 
plasma and tissue homogenates were estimated using 
the method described by Nourooz-Zadeh et al. [27]. 
Plasma or tissue homogenate (90 µl) was mixed with 
either 10 µl of 10 mM triphenylphosphine (TPP) in 
methanol or with 10 µl of methanol and incubated for 
30 min at a room temperature. Then, 900 µl of FOX2 
reagent (250 µM ammonium ferrous sulfate, 100 µM. 
xylenol orange, 25 mM H2SO4 and 4 mM butylated 
hydroxytoluene in 90 % methanol) was added and the 
mixture was incubated for another 30 min. The mixture 
was then centrifuged at 12 000 × g for 10 min to 
remove flocculated material and the absorbance was 
read at 560 nm. The absorbance of the sample with 
TPP was subtracted from the sample without TPP and 
lipid hydro¬peroxides concentration was calculated 
from the standard curve prepared using different 
concentrations (1–20 µM) of H2O2. 
Determination of PON1 paraoxonase activity 
Paraoxonase activity of PON1 was determined in 
plasma and tissue homogenates using paraoxon (O, O – 
diethyl-o-p-nitrophenylphosphate) as the substrate. The 
increase in absorbance at 405 nm due to the formation 
of 4-nitrophenol following the hydrolysis of paraoxon 
was measured as described by Furlong et al. [28]. 
Sample (20 µL) was added to 760 µL of the assay 
buffer containing 0.132 mol L-1 Tris-HCl, pH 8.5, and 
1.32 mM CaCl2. The substrate, paraoxon in 50 mmol 
L-1 Tris-HCl (200 µl), was added to initiate the 
reacion. The change in absorbance was continuously 
monitored on the Genesys 10S UV-VIS 
spectrophotometer for 3 min. Molar extinction 
coefficient of 18,050 was used to calculate enzyme 
activity. One unit of paraoxonase activity was defined 
as enzyme quantity that disintegrated one micromole of 
paraoxon substrate in 1 min at 25 °C. 
Estimation of lipid peroxidation product from liver 
homogenates.  
Lipid peroxidation in terms of thiobarbituric acid 
reactive substances (TBARS) formation was measured 
using the method of Esterbauer and Cheeseman [29]. 
Sample containing 1 mg protein was mixed with 1 ml 
TCA (20 %), 2 ml TBA (0.67%) and heated for 1 h at 
100oC. After cooling, the precipitate was removed by 
centrifugation. The absorbance of the sample was 
measured at 535 nm using a blank containing all the 
reagents except the sample. TBARS concentration of 
the liver samples were calculated using the extinction 
coeffecient of MDA which is 1.56 × 10−5 mmol−1 cm−1 
since 99% of TBARS exists as MDA. 
Estimation of CAT activity.  
The activity was measured in different homogenates by 
the method of Bonaventura et al. [30]. The enzyme 
CAT converts H2O2 formed via the action of SOD on 
superoxide radical into water. Protein from each 
sample was mixed with 7.5 mM H2O2 and a time scan 
was performed for 10min at 240 nm at 25oC. The 
disappearance of peroxide depending on the CAT 
activity was observed. One unit of CAT activity is 
defined as the amount of enzyme, which reduces 1 
µmol of H2O2 per minute. 
Estimation of SOD activity.  
The activity of SOD was assayed following the method 
originally developed by Nishikimi [31] and then 
modified by Kakkar et al. [32]. The sample was mixed 
with sodium pyrophosphate buffer, phenazine 
methosulphate (PMT) and nitro blue tetrazolium 
(NBT). The reaction was started by the addition of 
NADH. Reaction mixture was then incubated at 30oC 
for 90 seconds and stopped by the addition of 1 ml of 
glacial acetic acid. The absorbance of the chromogen 
formed was measured at 560 nm. One unit of SOD 
activity is defined, as the enzyme concentration 
required inhibiting chromogen production by 50% in 
one minute under the assay condition.  
Liver histopathology 
Liver specimens from all the experimental groups were 
fixed in 10% buffered formalin and were processed for 
paraffin sectioning. The processed sections were 
stained with haematoxylin-eosin and observation of the 
general structure of the liver was performed under light 
microscopy. 
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Statistical analysis 
Results are expressed as mean ± SD (n=7). One-way 
analysis of variance (ANOVA) followed by Tukey’s 
test was used to analyze the results with p < 0.05 
considered significant. 
Results 
Effect of treatment on body weight and relative liver 
weight.Table 1 depicts the effect of crocin on the body 
and liver weights of rats treated with 5-FU. Treatment 
with crocin alone resulted in about 6% weight gain, 
which was comparable and not significantly different 
to that gained by the control (p>0.05). All other groups 
administered with 5-FU exhibited significant reduction 
in weight (p<0.05). 5-FU alone resulted in 23% 
reduction in weight. Crocin treatment however, 
reversed some of the weight loss with a gain of about 
14%, 12% and 10% more than the 5-FU only group for 
the pre-treated, concurrent and post-treatment groups 
respectively. The ratio of liver weight to 100 g body 
weight was significantly increased by 5-FU 
administration (p<0.05). However, crocin alone and the 
crocin-treated groups displayed no changes in the 
relative liver weight compared to the control.  
                              
Table 1: Effects of crocin on body and liver weights of 5-Fluorouracil treated rats 
Group Body weight 
(% of initial body weight) 
Relative liver weight* 
(g/100 g body weight) 
Control 108.14 ± 2.67a 3.32 ± 0.96a 
5-FU alone 77.14 ± 5.58b 4.31 ± 0.61b 
Crocin alone 106.23 ± 3.05a 3.57 ± 0.27a 
Pretreatment 91.54 ± 5.71c 3.76 ± 0.60d 
Concurrent 89.82 ± 6.72c 3.65 ± 0.27c 
Post-treatment 87.51 ± 4.96c 3.85 ± 0.38d 
Values are expressed as mean ± SD, n=7. Values in the same column bearing the same superscript letter are 
not significantly different from each other, at p < 0.05. 
 
Effect of crocin on plasma activities of ALT, ALP and AST in 5-FU-treated rat 
Activities of the enzymes ALT, ALP and AST are considered biochemical marker of hepatic injury. These 
parameters were determined to ascertain whether crocin can attenuate the liver damage induced by 5-FU treatment 
(Fig. 1). In 5-FU-treated rats, the activities of ALT, ALP and AST significantly increased from 28.90 ± 2.67, 140.30 
± 5.42, and 78.74 ± 2.62 U/L in control to 49.86 ± 4.15, 209.66 ± 4.98, and 116.68 ± 2.68 U/L, respectively. 
However, the 5-FU-induced increases were lowered by crocin treatment. Pretreatment with crocin attenuated 5-FU 
effect on these activities by 23%, 14% and 20% respectively while concurrent treatment yielded a reduction of 32%, 
22% and 25% respectively. Post-treatment with crocin lowered the activities of these enzymes in 5-FU 
administration by 24%, 10% and 18% respectively. 
 
Fig 1: Effects of crocin treatment on plasma ALT, ALP and AST levels in 5-FU-treated rats. Each value is expressed as 
mean ± SD (n = 7). Different lowercase letters indicate a significant difference between groups at p < 0.05
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Effects of crocin on levels of MDA, LOOH, AOPP 
and FRAP 
5-FU produced significant increase in MDA levels in 
the liver. Its treatment generated a 45% increase in 
lipid peroxidation products, from 1.24 ± 0.12 nmol/mg 
protein in control to 1.89 ± o.31 nmol/mg protein in 5-
FU treated group (Fig. 2A). The increase was 
accompanied be elevation of plasma lipid 
hydroperoxide concentration of about 126% (Fig. 3A). 
Crocin displayed significant lipid peroxidation 
lowering ability and was able to ameliorate the 5-FU 
induced lipid peroxidation observed in the study. 
Pretreatment with crocin reduced the 5-FU generated 
hepatic MDA concentration to 1.47 ± 0.13 nmol/L 
while lowering the level of LOOH from 27.24 ± 0.45 
µmol/L to 19.57 ± 0.34 µmol/L. Concurrent treatment 
with crocin further reduced LOOH level to 17.24 ± 
0.22 µmol/L while post-treatment lowered it to 19.07 ± 
0.20 µmol/L. MDA concentrations were similarly 
reduced by the three crocin treatments. The results 
revealed significant elevation of both liver and plasma 
AOPP concentrations, as induced by 5-FU (Fig. 2C and 
3C). 5-FU administration resulted in significant 118% 
and 84% increases in liver and plasma AOPP levels 
respectively, in the rats (p<0.05). Concurrent treatment 
with crocin produced the largest reduction of these 
oxidant modified proteins. The treatment reduced the 
levels in the 5-FU-treated rats by 39% and 34%, 
respectively. Hepatic concentration of the modified 
proteins reduced by 26% and 34% after post- and pre-
treatment with crocin respectively, while plasma level 
were lowered by 24% and 23% respectively (Figs. 2c 
and 3C). 5-FU caused a significant reduction in hepatic 
total antioxidant capacity measured as FRAP, lowering 
the antioxidant potential by 2.5 fold, when compared to 
the control group (Fig. 2B.). Crocin alone significantly 
elevated the antioxidant power of the liver from 16.04 
± 0.88 µmol/mg protein in the control group to 19.13 ± 
0.46 µmol/mg protein, a significant 19% increase. 
Similarly, crocin improved the FRAP value from 6.53 
± 0.51 µmol/mg protein obtained in 5-FU treatment to 
11.43 ± 0.46 µmol/mg protein, 15.37 ± 0.51 µmol/mg 
protein and 12.76 ±0.65 µmol/mg protein in pre-, 
concurrent and post-treatment respectively. Plasma 
total antioxidant capacity was also equally improved by 
crocin treatments (Fig. 3B). Pre-, concurrent and post-
treatment with crocin enhanced antioxidant capacity in 
5-FU treatment by 40%, 57% and 61% respectively. 
 
 
Fig 2: Effects of crocin on hepatic levels of MDA (A), FRAP (B) and AOPP (C) in 5-FU-treated rats. Each 
value is expressed as mean ± SD (n = 7). Different lowercase letters indicate a significant difference between 
groups at p < 0.05. 
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Fig. 3: Effects of crocin on plasma levels of LOOH (A), FRAP (B) and AOPP (C) in 5-FU-treated rats. Each 
value is expressed as mean ± SD (n = 7). Different lowercase letters indicate a significant difference between 
groups at p < 0.05 
Effects of crocin on activities of antioxidant enzymes  
Figures 4 and 5 depict the activities of enzymatic antioxidants, plasma PONase in addition to plasma and liver SOD 
and CAT activities. A significant decrease (p<0.05) in the plasma activities (Fig. 4A, B and C) of these enzymes 
was observed after 5-FU administration (24.67 ± 2.65 U/ml, 30.98 ± 3.53 U/ml, and 0.45 ± 0.04 U/ml from 47.07 ± 
2.07 U/ml, 53.07 ± 3.01 U/ml, and 0.94 ±  0.05 U/ml in control respectively). Activities of CAT and SOD in the 
liver (Fig. 5A and B) were also marked reduced by 5-FU administration. The drug caused a depression of these 
enzymes’ activities from 74.06 ± 3.62 U/mg protein and 12.58 ± 0.65 U/mg protein to 43.38 ± 4.68 U/mg protein 
and 6.76 ± 0.67 U/mg protein respectively, a loss of more than 40% for either protein. Crocin treatments 
significantly enhanced the enzymes’ activities by reversing some of the inhibitory effect of 5-FU. Pre-, concurrent 
and post-treatment with crocin stimulated hepatic CAT by 63%, 66% and 60% respectively and SOD by 30%, 44% 
and 22% respectively. 
 
Fig 4: Effect of crocin on plasma PONase (A), SOD (B) and CAT (C) activities in 5-FU-treated rats. Each 
value is expressed as mean ± SD (n = 7). Different lowercase letters indicate a significant difference between 
groups at p < 0.05. 
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Fig. 5: Effect of crocin on liver CAT (A) and SOD (B) activities in 5-FU-treated rats. Each value is expressed 
as mean ± SD (n = 7). Different lowercase letters indicate a significant difference between groups at p < 0.05. 
Histopathological changes  
Light microscopy observation showed that the control 
liver tissue displayed normal hepatic lobules and plates 
radiating outward from a central vein (Fig. 6A). 
Animals administered with 5-FU showed signs of 
visible histology changes in the liver including 
structure damage, hepatocellular degeneration and 
disruption of cord-like pattern, changes that are not 
present in the liver of normal rats (Fig. 6B). Liver 
tissue from rats administered crocin alone exhibited 
normal histological structure similar to the control (Fig. 
6C). Liver sections of rats treated with crocin prior 
(Fig. 6D), along with (Fig. 6E) and after (Fig. 6F) 5-FU 
administration showed improvement on the pattern of 
hepatic lesions displayed by 5-FU alone, with the 
severity of lesions reduced significantly. 
 
   
``   
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Fig 6:  Photomicrographs of control and treated rat liver, H&E 100x. (A) Control rat showing normal 
hepatocytes, central canal and sinusoids. (B) Section of rat liver treated with 5-FU alone showing massive loss 
of tissue structural pattern, signs of fat droplets and fibrous appearance. (C) Crocin alone had no marked 
histological alteration except enlargement of the central vein and the sinusoids. (D) Pre-treatment with crocin 
restored partial histology with enlargement of the sinusoids, accompanied by shrinkage of hepatocytes and 
hemorrhage of the central vein. (E) Concurrent application of crocin with 5-FU showed a more improved 
restoration of the hepatic histology but with contracted central vein and increased presence of leukocytes. (F) 
Post-treatment with crocin after 5-FU administration displayed enlargement of both sinusoids and the central 
vein but with distortion of the structural histology. 
Discussion 
Although a number of studies have been carried out on 
the protective effect of natural agents against 
chemotherapeutic drugs, this present study, to the best 
of our knowledge, would be the first to investigate the 
potential protective effect of crocin against 5-
fluorouracil induced liver damage. 5-FU is a potent 
anti-neoplastic drug, however, its hepatotoxic side 
effects potentially decreases its therapeutic value in the 
treatment of cancer. On the other hand, crocin has 
demonstrated hepatoprotective properties [21]. This 
study therefore, evaluated the ability of crocin to 
protect against 5-FU induced hepatic injury. The 
results of the present study suggest a beneficial role of 
crocin in reversing some hepatotoxic effects of 5-FU in 
rats by improving a number of biochemical variables 
and parameters indicative of hepatic injury and 
oxidative stress. Rats administered 5-FU were pre-, 
concurrently and post-treated with crocin and the 
treatments were compared. Overall, the data showed 
that concurrent crocin administration proved more 
effective compared with either pretreatment or post-
treatment.Oxidative stress results when generation of 
excess reactive oxygen species exceeds the capacity of 
the antioxidant system [33]. These reactive species 
mediate cell damage in a variety of pathophysiological 
conditions and are responsible for severe damage to 
macromolecules, tissues and organs through lipid 
peroxidation (LPO), protein modification and DNA 
strand breaks [33, 34]. The effect of 5-FU 
administration on lipid peroxidation was assessed by 
estimating the hepatic MDA and plasma 
hydroperoxides concentrations. 5-FU significantly 
elevated both indices in the two compartments. The 
increased hepatic lipid peroxidation evidenced by the 
elevated MDA concentration is an indication that 5-
FU-induced hepatic damage is mediated in part, by the 
generation of free radicals.  Supporting the generation 
of reactive oxygen species by 5-FU is the elevation of 
advanced oxidative protein products (AOPP) in these 
animals. AOPP are dityrosine-containing crosslinked 
protein products and are important markers of degree 
of oxidant-mediated protein damage [35].  Increased 
production of ROS is known to be accompanied with 
the generation of oxidized proteins [36]. Crocin 
treatments attenuated both the increased lipid 
peroxidation and the oxidant mediated protein damage 
caused by the increased oxidative stress, indicative of 
the antioxidant property of crocin. Increased oxidative 
stress typified by the high peroxidation levels, also 
signifies a 5-FU-induced depletion of the antioxidant 
system. Furthermore, 5-FU reduced intracellular 
antioxidant power, as manifested by the lowered FRAP 
level in the 5-FU group. The antioxidant capacity of 
the liver was determined by the FRAP assay and it 
provides a wider representation of the relative 
antioxidant activity of all antioxidants present in the 
tissue. The reduction in total antioxidant capacity by 5-
FU is reflective of antioxidant imbalance, an indication 
that the capacity of the antioxidant system has been 
exceeded. All these changes were significantly 
improved by treatment with crocin, prior, with and 
after 5-FU administration. This suggests that crocin 
performed an antioxidant role in 5-FU induced 
generation of ROS, probably by stabilizing the 
antioxidant system in the rats. Furthermore, plasma and 
hepatic activity of the antioxidant enzymes CAT, SOD 
and plasma PONase, an enzyme with hepatic origin, 
were inhibited by 5-FU treatment in the rats. The 
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reduced activity of these enzymes could be due to 
enhanced lipid peroxidation or inactivation of these 
proteins by the anti-neoplastic drug. Data from this 
study demonstrated that crocin has a positive effect in 
reversing the effect of 5-FU on these enzymes. 
Concurrent and post treatment with crocin restored 
hepatic SOD activity to near the control range while 
concurrent treatment completely reversed hepatic CAT 
activity back to normal. Treatment with 5-FU caused 
pronounced increase in plasma ALT, AST and ALP 
activities of the rats, indicating severe hepatotoxicity. 
This is in agreement with previous study showing 
elevation of these enzymes in 5-FU treatment [37]. The 
excess production of oxidants resulting in oxidative 
stress and the accumulation of oxidation products in 
the liver, as observed in this study apparently has 
damage biological membranes and the endothelium 
lining of the liver. This likely contribute to the hepatic 
injury leading to the high flux of the transaminases 
found in the blood. Transaminases are considered the 
most important biomarkers directly associated with the 
extent of cellular damage and toxicity [38]. Significant 
elevation of plasma AST, ALT and ALP activities have 
been employed as reliable markers of acute liver injury 
[39, 40]. ALT, a cytosolic enzyme is more specific for 
the liver, while AST is located in mitochondria and is 
mainly found in the liver, skeletal muscles and kidneys. 
ALP is an enzyme which activity is increased in the 
plasma as a result of obstruction or inflammation of the 
biliary tract.  Increase in their activities in the blood is 
majorly a result of leakage of these transaminases from 
the hepatocytes into the circulation, indicating liver 
damage or dysfunction.  Crocin application prior, with 
or after 5-FU administration induced significant 
recovery in these variables, causing significant lowered 
activities of these enzymes which is  suggestive of 
reduced hepatotoxicity in the animals exposed to 5-FU. 
However, rats concurrently treated with 5-FU and 
crocin showed significantly better reduction in plasma 
ALT, AST and ALP values compared to both pre and 
post treatment with the carotenoid.Histological 
examination of the liver reveals that 5-FU treatment 
caused abnormal ultrastructural changes in the organ. 
In crocin treated animals, the changes were less 
compared to the 5-FU group, showing that crocin 
administration could improve the changes brought 
about by the drug on the liver.  Crocin has been 
reported to display antioxidant effects and the present 
study provides further evidence for this as reflected by 
its effectiveness at the tested dose, in reducing 5-FU-
induced elevated tissue oxidative damage, typified by 
high lipid hydroperoxides, MDA and AOPP 
concentrations and restoring the antioxidant system 
through the improvement of hepatic antioxidant power, 
in addition to stimulating the antioxidant enzymes. It 
was also able to reduce 5-FU-induced hepatotoxicity 
depicted by its correction of the altered liver function 
indices and improve the histopathological damage 
inflicted by the drug. On the whole, the study 
demonstrated that crocin has considerable protective 
potential against 5-fluorouracil induced oxidative stress 
and hepatic damage and at a higher dose, could 
effectively protect against the toxicity. 
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